Lenvima

Lenvima

None

None

None

October 2014: FDA granted priority review status to lenvatinib mesylate as a treatment for progressive radioactive iodine-refractory differentiated thyroid cancer. Lenvatinib was granted orphan drug designation in various types of thyroid cancer in the US, Japan, and Europe. It is currently under investigation in thyroid, hepatocellular, endometrial, non-small cell lung cancer, and other solid tumor types.

May 13, 2016 FDA approved lenvatinib capsules (Lenvima, Eisai, Inc.), in combination with everolimus, for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy. Lenvatinib was first approved in 2015 for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

August 16, 2018: FDA approved lenvatinib capsules (Lenvima) for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

Sept. 3, 201 Keytruda plus Lenvima have received FDA approval as first-line treatment of adult patients with advanced renal cell carcinoma. Coding note: code each agent in the appropriate treatment fild: Lenvima in chemotherapy and Keytruda in BRM.

This drug should be coded